177 related articles for article (PubMed ID: 38397058)
21. Determination of biomarkers associated with neoadjuvant treatment response focusing on colibactin-producing
Taoum C; Carrier G; Jarlier M; Roche G; Gagniere J; Fiess C; De Forges H; Chevarin C; Colombo PE; Barnich N; Rouanet P; Bonnet M
BMJ Open; 2022 Dec; 12(12):e061527. PubMed ID: 36460331
[TBL] [Abstract][Full Text] [Related]
22. [Two Cases of Unresectable Advanced Rectal Cancer with a Long-Term Survival for Which Pathological Complete Response Was Achieved through Neoadjuvant Effective Chemotherapy].
Gonda K; Tachiya Y; Hatakeyama Y; Shibata M; Kono K; Rokkaku Y
Gan To Kagaku Ryoho; 2017 Oct; 44(10):944-946. PubMed ID: 29066704
[TBL] [Abstract][Full Text] [Related]
23. Tissue-Based Markers as a Tool to Assess Response to Neoadjuvant Radiotherapy in Rectal Cancer-Systematic Review.
Smolskas E; Mikulskytė G; Sileika E; Suziedelis K; Dulskas A
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682714
[TBL] [Abstract][Full Text] [Related]
24. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
[No Abstract] [Full Text] [Related]
25. High SLC28A2 expression endows an inferior survival for rectal cancer patients managed by neoadjuvant CCRT.
Chen HP; Chen CI; Liu KW; Chen TJ; Tian YF; Kuo YH; Li WS; Tsai HH; Wu LC; Yeh CF; Li CF; Chou CL; Lai HY
Pathol Res Pract; 2022 Nov; 239():154158. PubMed ID: 36244249
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.
Glynne-Jones R; Hava N; Goh V; Bosompem S; Bridgewater J; Chau I; Gaya A; Wasan H; Moran B; Melcher L; MacDonald A; Osborne M; Beare S; Jitlal M; Lopes A; Hall M; West N; Quirke P; Wong WL; Harrison M;
BMC Cancer; 2015 Oct; 15():764. PubMed ID: 26493588
[TBL] [Abstract][Full Text] [Related]
27. Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer.
Jia H; Shen X; Guan Y; Xu M; Tu J; Mo M; Xie L; Yuan J; Zhang Z; Cai S; Zhu J; Zhu Z
Radiother Oncol; 2018 Sep; 128(3):548-556. PubMed ID: 30041962
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy (CAPOX) alone for low- and intermediate-risk stage II/III rectal cancer: Long-term follow-up of a prospective single-arm study.
Shen Y; Wu Q; Meng W; Wei M; Deng X; Wang Z
Eur J Surg Oncol; 2023 Dec; 49(12):107115. PubMed ID: 37839296
[TBL] [Abstract][Full Text] [Related]
29. Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy.
Trotsyuk I; Sparschuh H; Müller AJ; Neumann K; Kruschewski M; Horst D; Elezkurtaj S
BMC Cancer; 2019 Nov; 19(1):1033. PubMed ID: 31675950
[TBL] [Abstract][Full Text] [Related]
30. Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
Naiken SP; Toso C; Rubbia-Brandt L; Thomopoulos T; Roth A; Mentha G; Morel P; Gervaz P
BMC Surg; 2014 Jan; 14():4. PubMed ID: 24438090
[TBL] [Abstract][Full Text] [Related]
31. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
32. Increased Lymph Node Yield Is Associated With Improved Survival in Rectal Cancer Irrespective of Neoadjuvant Treatment: Results From a National Cohort Study.
Lykke J; Jess P; Roikjaer O;
Dis Colon Rectum; 2015 Sep; 58(9):823-30. PubMed ID: 26252843
[TBL] [Abstract][Full Text] [Related]
33. A contemporary assessment of total neoadjuvant therapy (TNT) protocols for locally advanced rectal cancer: adoption and expert perspectives at German Cancer Society (DKG)-certified colorectal cancer centers.
Langheinrich M; Paasch C; Mantke R; Weber K; Benz S; Kersting S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12591-12596. PubMed ID: 37438538
[TBL] [Abstract][Full Text] [Related]
34. Effect of aspirin use on neoadjuvant chemoradiotherapy for rectal cancer: a meta-analysis with trial sequential analysis.
Wang B; Huang Y
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2161-2171. PubMed ID: 32328776
[TBL] [Abstract][Full Text] [Related]
35. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.
Ryan JE; Warrier SK; Lynch AC; Ramsay RG; Phillips WA; Heriot AG
Colorectal Dis; 2016 Mar; 18(3):234-46. PubMed ID: 26531759
[TBL] [Abstract][Full Text] [Related]
36. Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project.
Pellino G; Alós R; Biondo S; Codina-Cazador A; Enríquez-Navascues JM; Espín-Basany E; Roig-Vila JV; Cervantes A; García-Granero E;
Eur J Surg Oncol; 2021 Feb; 47(2):276-284. PubMed ID: 32950316
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer.
Kanani A; Veen T; Søreide K
Br J Surg; 2021 Dec; 108(12):1417-1425. PubMed ID: 34694371
[TBL] [Abstract][Full Text] [Related]
38. The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation.
Dudani S; Marginean H; Gotfrit J; Tang PA; Monzon JG; Dennis K; Kennecke HF; Powell ED; Babak S; Cheung WY; Vickers MM
Dis Colon Rectum; 2021 Dec; 64(12):1471-1478. PubMed ID: 34657078
[TBL] [Abstract][Full Text] [Related]
39. The Role of Micro-RNAs and Circulating Tumor Markers as Predictors of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
De Palma FDE; Luglio G; Tropeano FP; Pagano G; D'Armiento M; Kroemer G; Maiuri MC; De Palma GD
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987896
[TBL] [Abstract][Full Text] [Related]
40. When Should We Expect Curative Results of Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients?
Georgescu MT; Patrascu T; Serbanescu LG; Anghel RM; Gales LN; Georgescu FT; Mitrica RI; Georgescu DE
Chirurgia (Bucur); 2021; 116(1):16-23. PubMed ID: 33638322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
